Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas - PubMed
4 hours ago
- #geriatric oncology
- #CAR-T therapy
- #large B-cell lymphoma
- Age does not significantly affect overall survival (OS), progression-free survival (PFS), or cytokine release syndrome (CRS) after CD19 CAR T-cell therapy for large B-cell lymphomas.
- Older age (≥65 years) is associated with an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS).
- Patients aged 65-74 years showed a lower relapse risk compared to younger patients.
- Nearly half (44%) of the 1916 recipients were aged ≥65 years, indicating significant use of CAR-T therapy in older adults.
- The overall rates of CRS and ICANS were 75% and 43%, with severe cases at 9% and 21%, respectively.
- 12-month outcomes for all patients included 62% OS, 42% PFS, and a 55% relapse rate.
- The study supports the effectiveness of CD19 CAR-T therapy in older adults, with age not worsening mortality but increasing ICANS risk.